The PennZone

  • Home
  • Business
  • Health
  • Construction
  • Real Estate
  • Technology
  • Entertainment
  • Education
  • Travel

Dr. Jeff Gelblum Provides Alzheimer's Treatment to Patients in the US and Abroad
The PennZone/10277342

Trending...
  • Accelerating the Transformation into a U.S. Nuclear Fuel Cycle Leader: Frontier Nuclear and Minerals Inc. (N A S D A Q: FNUC)
  • New Report Reveals Surprising Trends in Ohio Airport Accidents
  • High-Growth Power Infrastructure Play Targets AI Boom: 1606 Corp. Executes Aggressive Texas Expansion Strategy: 1606 Corp. (Stock Symbol: CBDW) $CBDW
Alzheimer's Treatment
AVENTURA, Fla. - PennZone -- Dr. Jeff Gelblum, Neurologist at First Choice Neurology, has brought together clinical, imaging, and laboratory capabilities to provide rapid diagnosis and treatment to individuals suffering from Alzheimer's disease.

The patient journey of Alzheimer's evaluation and management involves a clinical assessment to determine the level of cognitive impairment, and imaging studies of the brain, MRI, and PET scans to identify the presence of brain amyloid plaques. Also included are laboratory capabilities to inform the tolerability of the new anti-Alzheimer medication, and an experienced infusion team capable of providing the new class of FDA-approved medication in a comfortable setting.

Dr. Gelblum's highly integrated program will eliminate the long delays and fragmented care that typically plague patients seeking Alzheimer's treatment.

He observes, "that the new class of disease-modifying treatments are only approved in mild Alzheimer's which offers only a short window of opportunity to treat. In the US and abroad, it can often take up to a year to get a neurology appointment, and by that point, the patient may have progressed to a point where they might no longer respond to treatment."

More on The PennZone
  • Best Companies Group Free Launches Best Places to Work in Michigan Program
  • Billy Bob Thornton & The Boxmasters Coming to The Eichelberger Performing Arts Center This August
  • EFA Announces 2026 Editorial Rate Chart
  • NYC Composer/Educator Launches Debut Children's Book to Fantastic Reviews
  • Red5 Taps PubNub to Power the Next Era of Real-Time Interactive Streaming

Dr. Gelblum's program eliminates the delay and provides a quick and comprehensive work-up in the Aventura medical district, just north of Miami, Florida.

Dr. Gelblum boasts that "within 48 hours we can diagnose and begin infusion therapy.  This means that the patient can check in to our on-campus hotel on a Tuesday evening, undergo evaluation in our clinic Wednesday morning, receive diagnostic testing Wednesday and Thursday, and then obtain their infusion treatment on Friday."

For those patients who reside out of town, his infusion center can dispense medication to-go for follow-up infusion treatments in their hometown medical facility. This is ideal for out-of-town patients who may not have easy access to a neurologist. He can then follow the patient remotely via telehealth.

His Aventura clinic is easily accessible via Miami or Fort Lauderdale international airports.

Dr. Gelblum has a global patient population who has discovered the ease of access and convenience of care provided by this program. He has patients from the UK, Spain, France, Israel, Russia, South Korea, Central and South America, and the Caribbean. They are diagnosed in his Aventura clinic and then followed up remotely via Skype, WhatsApp, FaceTime, or any manner of live audiovisual interface.

More on The PennZone
  • Shoutout Joseph Neibich aka Nybyk
  • Meet Joseph Neibich aka Joseph Nybyk of Beachwood Canyon
  • LARUS Launches Business Continuity Framework for IPv4-Dependent Networks
  • KeysCaribbean Offers 'Skip-the-Crowds' Savings With 15 Percent Off April Stays
  • Supply & Demand Chain Executive Names Puga Sankara as Recipient of 2026 Pros to Know Award

Dr. Gelblum observes, "that in this day and age of disease-modifying therapy and instantaneous telecommunications, it is unacceptable for medically necessary neurological care and treatment to be delayed."

He looks forward to welcoming Alzheimer patients from all over to his Aventura, Florida clinic.

About Jeffrey Gelblum, MD, FAAN

Dr. Jeff Gelblum is a neurologist with First Choice Neurology located in Aventura, Florida. He is considered a global thought leader in the neurologic treatment of Alzheimer's, dementia, seizure disorders, Parkinson's, diabetic and peripheral nerve disorder, Familial Amyloid Polyneuropathy, Covid Long-Hauler, trauma, and chronic pain, and has hosted educational symposia in the U.S. and overseas. To learn more about Dr. Gelblum, visit https://www.fcneurology.net/business-directory/788/jeffrey-gelblum-md/

Contact
First Choice Neurology
***@fcneurology.net


Source: First Choice Neurology

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • The World's First Fully Regenerative Economy: Securing Energy, Food, and a Clean Planet
  • The State of Law Firm Marketing: Top Companies, Awards, and Resources
  • USA Best Book Awards Finalist What Love Leaves Behind Releases March 24
  • Inkdnylon Custom Apparel Launches Cost-Saving System for Promotional Products and Custom Apparel in Chicago
  • Colonial Nissan Helps Drivers Avoid Costly Repairs with Spring Car Maintenance Tips
  • ENTOUCH Named Finalist for 2026 North American Inspiring Workplaces Awards
  • Cleveland County Goat Farm NC Kikos Featured in "Feature Farmer Friday" Documentary
  • Tony Grundler Introduces Artificial Intelligence V.S. Avatar-Ian's
  • Hollywood's Elite Gather at the Annual WOW Creations Oscars Gifting Suite at the Universal Hilton
  • Where Were the Women? Reframing the Greek Revolution Through Contemporary Art
  • IWS Press Publishes "Smart Money Shortcuts to Becoming Rich" by Tyler G. Hicks
  • JGCMGS Details Architecture to Safeguard Assets From Unauthorized Phishing Scams
  • 21 Days: The Malta Deadline That Could Redraw the Finnish Online Casino Map
  • JEGS Launches Modern, Secure Payments Powered by PhaseZero.ai
  • U.S. Government Contracts in Excess of 38 Million Secured Through Partner, Establishing Multi-Year Defense Revenue Platform Through 2032: $BLIS
  • New Report Reveals Surprising Trends in Ohio Airport Accidents
  • Why Your Berberine Failed: RevGenetics Unveils the Absorption Gap Solution
  • WCC Kitchens and Cabinets Featured on Selling Houses Australia
  • Cat Hunt Simulator : Burrow & Pounce Lands on the App Store
  • Shincheonji Marks 42nd Anniversary: From a Basement to a Denomination Growing by Tens of Thousands Annually

Popular on PennZone

  • Postmortem Pathology Expands Independent Autopsy Services Across Colorado
  • Progressive Dental & The Closing Institute Partner with Zest Dental Solutions to Elevate Full-Arch Growth and Patient Outcomes
  • Mecpow M1: A Safe & Affordable Laser Engraver Built for Home DIY Beginners
  • Platinum Car Audio LLC Focuses on Customer-Driven Vehicle Audio and Electronics Solutions
  • New Book Warring From the Standpoint of the Throne Room Calls Believers to Pray From Victory
  • Postmortem Pathology Expands Independent Autopsy Services in Kansas City
  • $38 Million in U.S. Government Contract Awards Secured Through Strategic Partner. Establishing Multi-Year Defense Revenue Platform Through 2032: $BLIS
  • Cummings Graduate Institute for Behavioral Health Studies Honors New Doctor of Behavioral Health Graduates
  • Inkdnylon Earns BBB Accreditation for Verified Business Integrity
  • 505 Plumbing, Heating & Cooling Launches in Albuquerque, Bringing a Customer-First Approach to Home Services

Similar on PennZone

  • Compliance Alert: Maryland, Texas Regulate Use of Artificial Intelligence in Utilization Reviews
  • Targeting the Billion-Dollar U.S. Countermeasure Market With AI-Driven Biodefense Platform: Lunai Bioworks (N A S D A Q: LNAI)
  • Forced Psychiatric Hospitalization Fails Vulnerable People: CCHR Urges Repeal Amid Rising U.S. Policies
  • Surging Into High-Performance AI With $AMD Partnership, Patent Expansion, and Strengthened Balance Sheet: Avalon GloboCare Corp. (N A S D A Q: ALBT)
  • Inkdnylon Custom Apparel Launches Cost-Saving System for Promotional Products and Custom Apparel in Chicago
  • Where Were the Women? Reframing the Greek Revolution Through Contemporary Art
  • Why Your Berberine Failed: RevGenetics Unveils the Absorption Gap Solution
  • Event Solutions Enters New Era: Announces New Leadership
  • CCHR Warns: Psychiatric Diagnoses Without Biological Proof Now Used to Justify Euthanasia
  • JL Tox Consulting Responds to New ISO 10993-1:2025 Biocompatibility Standard Release
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us